Basic research for a new concurrent treatment against lifestyle diseases and Alzehimer disease.
| Project/Area Number |
18H02732
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52010:General internal medicine-related
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中神 啓徳 大阪大学, 医学系研究科, 寄附講座教授 (20325369)
沢村 達也 信州大学, 学術研究院医学系, 教授 (30243033)
武田 朱公 大阪大学, 医学系研究科, 寄附講座准教授 (50784708)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥12,870,000 (Direct Cost: ¥9,900,000、Indirect Cost: ¥2,970,000)
Fiscal Year 2021: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2020: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | 認知症 / アルツハイマー病 / 生活習慣病 / ワクチン / アンジオテンシンII受容体 / AGE受容体 / アミロイドβ / アンジオテンシン / レニン-アンジオテンシン系 |
|---|
| Outline of Final Research Achievements |
Based on our findings that the type 1 receptor of angiotensin II (AII) (AT1), which regulates blood pressure, is responsible for the cellular response of amyloid-β (Aβ), which promotes Alzheimer's disease (AD), we conducted a basic study to investigate whether vaccine therapy against AT1 could be a disease-modifying-drug for AD. First, we confirmed that three anti-AT1 vaccines suppressed AII-induced hypertensive response in mice. We also confirmed that mouse serum after anti-AT1 vaccine administration or purified anti-AT1 antibody inhibited intracellular Aβ uptake. On the other hand, when one type of anti-AT1 vaccine was administered to aged mice and their cognitive function was evaluated 6 months later, there was no apparent improvement in cognitive function compared to the control vaccine.
|
| Academic Significance and Societal Importance of the Research Achievements |
アルツハイマー型認知症(AD)の根本的治療薬(DMT)は未だに確立されておらず、研究の進展が望まれている。本研究は独自の研究結果に基づいて、アンジオテンシンII1型受容体(AT1)に対するワクチンがAD治療に有効であるか基礎的に検証する計画であった。研究成果からはアミロイドβ(Aβ)がADを促進する細胞反応を抗AT1ワクチンで産生される抗体が抑制する結果が得られたが、高齢マウスの認知機能の改善作用は認められなかった。本研究の過程でAT1に対する阻害療法がADを改善することを支持する研究成果が得られており、今後も継続的に検討を行うことでADのDMT開発につながることが期待される。
|
Report
(5 results)
Research Products
(2 results)
